awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q27853078-4E78D421-76E6-47BE-9AD1-CA39D138DA53
Q27853078-4E78D421-76E6-47BE-9AD1-CA39D138DA53
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27853078-4E78D421-76E6-47BE-9AD1-CA39D138DA53
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
P2860
Q27853078-4E78D421-76E6-47BE-9AD1-CA39D138DA53
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27853078-4E78D421-76E6-47BE-9AD1-CA39D138DA53
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f44955de230a9e78d1af2387a2f816d026b74980
P2860
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.